PDAC Biomarker Panel for Early Detection Accuracy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for imaging modalities and biomarker CA19-9 alone have limited performance as a diagnostic tool for the detection of pancreatic cancer at an early stage.
Innovation Solution
The present disclosure provides methods and kits for the early detection of pancreatic cancer. The methods and kits use multiple assays of biomarkers contained within a biological sample obtained from a subject. The combined analysis of at least three biomarkers: carbohydrate antigen 19-9 (CA19-9), TIMP metallopeptidase inhibitor 1 (TIMP1), and leucine-rich alpha-2-glycoprotein 1 (LRG1), provides high-accuracy diagnosis of PDAC when screened against cohorts with known status.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If CA19-9 alone is used as a biomarker for PDAC detection, then the diagnostic process is simple, but the detection accuracy is insufficient with high false positive and negative rates
Solution Approach 1:
The patent combines multiple biomarkers (CA19-9, TIMP1, LRG1, and other proteins or metabolites) into a panel for PDAC detection. This merging of multiple diagnostic indicators resolves the contradiction by maintaining relative simplicity through standardized assays while dramatically improving detection accuracy and reducing false positives compared to single biomarker approaches.
2Measurement precision
If multiple biomarkers are analyzed for PDAC detection, then the detection accuracy improves, but the diagnostic process complexity increases
Solution Approach 1:
The patent employs universal assay platforms (such as ELISA, mass spectrometry, or other standardized biochemical assays) that can detect multiple biomarkers simultaneously. This multi-functionality approach allows the diagnostic system to analyze numerous biomarkers for improved accuracy while maintaining operational simplicity through established laboratory techniques, resolving the complexity-accuracy tradeoff.
3Ease of operation
If CA19-9 is used as a standalone biomarker, then the test is easy to perform, but the reliability of diagnosis is low due to limited sensitivity and specificity
Solution Approach 1:
The patent merges CA19-9 with additional biomarkers (TIMP1, LRG1, and other proteins or metabolites) to create a composite diagnostic panel. This combination maintains ease of operation through standardized assays while significantly improving diagnosis reliability by reducing false positives and negatives, as each biomarker provides complementary information about PDAC presence.
4Measurement precision
If imaging modalities are used for PDAC detection, then structural information is obtained, but early-stage detection capability is limited
Solution Approach 1:
The patent introduces biomarker analysis as an intermediary diagnostic tool that can detect PDAC at earlier stages than imaging modalities alone. By measuring biochemical indicators (proteins, metabolites) in blood or other fluids, the system achieves superior early-stage detection capability while maintaining relatively simple laboratory-based procedures, complementing rather than replacing imaging approaches.
Data Source
AI summary
Provided are methods and related kits for detection of early stage pancreatic ductal adenocarcinoma. Also provided are methods for treating a patient susceptible, or suspected of being susceptible, to pancreatic ductal adenocarcinoma.